CSOP HEALTHCARE

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

01801

159316

159570

159992

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

INNOVENT BIO

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

02268

WXXWY

02269

513700

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

iShares US Pharma

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Penghua CSI HK Connect Health Care Composite ETF

iShares Biotechnology ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

02513

02476

03986

06869

06613

02015

01209

09926

00175

01109

KNOWLEDGE ATLAS(02513) rose 9.33%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 878.5%. VGT(02476) rose 8.47%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 75.7%. LI AUTO-W(02015) fell 14.15%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 0.1%. CHINA RES MIXC(01209) fell 6.19%, with a trading turnover 346.3 Million HKD, and a year-to-date rose 6.7%.

- The Hang Seng Index decreased by 1.11%, with a year-to-date increase of 0.2%.  
- The Hang Seng Tech Index fell by 1.95%, reflecting a year-to-date decline of 12.2%.  
- Notable stock movements include Zhizhu's 9.33% increase and an 878.5% cumulative rise for the year, alongside Lixiang Auto's 14.15% drop with minimal year-to-date growth.

Top Gainers&Losers

KNOWLEDGE ATLAS

GIGADEVICE

YOFC

Lens

LI AUTO-W

CHINA RES MIXC

AKESO

GEELY AUTO

CHINA RES LAND

Top 5 HK Stock Gainers/Losers (>100B) (5.18)

02050

00501

01347

06082

02600

01208

SANHUA(02050) rose 6.84%, with a trading turnover 1.8 Billion HKD, and a year-to-date fell 6.3%. Lens(06613) rose 5.23%, with a trading turnover 779.6 Million HKD, and a year-to-date fell 11.4%. YOFC(06869) fell 12.14%, with a trading turnover 5.0 Billion HKD, and a year-to-date rose 331.3%. HUA HONG SEMI(01347) fell 8.74%, with a trading turnover 7.1 Billion HKD, and a year-to-date rose 56%.

SANHUA

OMNIVISION

HUA HONG SEMI

BIREN TECH

CHALCO

Top 5 HK Stock Gainers/Losers (>100B) (5.15)

06160

Citic Securities has reaffirmed its Buy rating for BeOne Medicines Ltd (6160) as of May 12, setting a price target of HK$234.00, while the shares closed at HK$189.90. The analyst consensus for the stock is Strong Buy, with a target consensus of HK$254.33, indicating a potential upside of 33.93%. Additionally, DBS also maintains a Buy rating with a price target of HK$290.00.

Tip Ranks

BEONE MEDICINES

Beigene

BeOne Medicines

CITIC SEC

CITIC Securities Co., Ltd.

Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

02509

603259

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WUXI APPTEC

SKB BIO

TEDA BIOMEDICAL

ICBCCS SSE STAR Biology and Medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Yesterday, WuXi Biologics' stock price quickly rose to HKD 120, with a trading volume reaching HKD 800 million, indicating active market participation. The MACD daily chart generated a golden cross above the zero line, further confirming the bullish trend in the pharmaceutical technology sector, with strong short-term performance. The current stock price is firmly above key technical levels, suggesting a positive outlook for the future. Amid the wave of pharmaceutical technology development, WuXi Biologics, as an important part of the biopharmaceutical CDMO platform, is actively engaged in new drug varieties and industry chain integration, receiving broad market optimism. Additionally, positive developments in Sino-U.S. trade relations and advancements in COVID-19 drug research provide a more solid foundation for expanding its market share. In terms of technical indicators, after the MACD daily chart showed a golden cross signal, it formed upward support on the moving averages, with significant buying volume and price coordination, and the continued warming of market confidence brings necessary conditions for profitability. However, it is important to note that the market's high valuation carries certain bubble risks, and investors should grasp market rhythms and adjust dynamically in a timely manner. Risk warnings include international legal regulations, global industrial chain arrangements, and vaccine development progress, which will continue to pose threats to its profitability. Market changes are rapid, and investors must base their decisions on well-equipped information to make rational choices. This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances

Technical Forecast

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Pre-market trend | WuXi Biologics (2269.HK) 5/11 Pharmaceutical technology sets the direction, initial results in new drug development?

688235

Yesterday's closing price for BeOne Medicines was HKD 190.5, with an intraday volatility of over 4%. The highest price reached HKD 191.8, while the lowest dipped to HKD 183.3, ultimately closing with a slight decline of 0.05%. The MACD daily line formed a golden cross signal above the zero axis, indicating that bullish momentum is re-accumulating in the previous upward trend, with phase buying pressure building up again. The total trading volume reached HKD 748 million, maintaining an active range as a leading stock in the biotechnology sector, with sustained investor interest. On the news front, the global biotechnology sector has recently gained continuous attention. As one of the most internationalized Chinese innovative pharmaceutical companies, BeOne Medicines' core pipelines such as PD-1 and BTK inhibitors are expected to see significant growth in overseas markets, which remains an important logic for institutional investment. Additionally, the Hong Kong stock market has recently benefited from expectations of diplomatic interactions between the U.S. and China—U.S. President Trump is scheduled to visit China from May 13 to 15, which the market interprets as a temporary easing of U.S.-China relations, likely reducing geopolitical uncertainties in the biopharmaceutical field and providing positive catalysts for companies like BeOne Medicines that have significant business in the U.S. From a technical perspective, BeOne Medicines' current stock price is operating near the 5-day and 10-day moving averages, with the short-term moving average system maintaining a bullish arrangement. Although there was significant volatility during the day, the final closing price remained stable near the opening price, indicating a temporary balance between bullish and bearish forces. After confirming the golden cross above the MACD zero axis, if the trading volume continues to stay above HKD 600 million in the following trading days, the momentum to test previous highs is expected to continue

Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start?

In a report released yesterday, from CMBC International maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$278.85.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released on May 7, DBS also maintained a Buy rating on the stock with a HK$290.00 price target.

BeOne Medicines Ltd (6160) Gets a Buy from CMBC International

01093

CONCORD HC GPannounced a proposal to issue HKD68 million in convertible bonds to a subsidiary of CSPC PHARMA. After expenses, net proceeds are expected to be around HKD63.1 million. Approximately 70% of the funds will be used to repay loans, while 30% will support working capital. The bonds will convert into 40 million H shares, equating to about 4.86% of the enlarged total issued shares.

CSPC PHARMA

CONCORD HC GP

CONCORD HC GP  Proposes to Issue HKD68 Million Convertible Bonds to CSPC PHARMA

CSOP HEALTHCARE(03174.HK)